T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).
The discovery of multiple subtypes of human immunodeficiency virus type 1 (HIV-1) worldwide has created new challenges for the development of both therapeutic and preventive AIDS vaccines. We examined T-helper proliferative responses to HIV-1 clade A, B, C, G, and E whole-killed virus and to HIV-1 clade G and B core (p24) antigens in HIV-1-infected subjects taking potent antiviral drugs who received HIV immunogen (Remune) therapeutic vaccination. Subjects who were immunized mounted strong proliferative responses to both whole virus and core antigens of the different clades. These results suggest that a whole-killed immunogen may have broad applications as a therapeutic as well as a preventive vaccine in the current multiclade HIV-1 pandemic.
Moss
R B
RB
The Immune Response Corporation, Carlsbad, California 92008, USA. shotdoc@imnr.com
Giermakowska
W
W
Wallace
M R
MR
Savary
J
J
Jensen
F
F
Carlo
D J
DJ
D016915:AIDS Vaccines / Q000276:immunology*; D002455:Cell Division; D016655:HIV Core Protein p24 / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology / Q000276:immunology* / Q000821:virology; D014611:Vaccination
D016915:AIDS Vaccines; D016655:HIV Core Protein p24; C105086:remune